Hytest is a pioneer in cardiovascular disease diagnostics and the inventor on patents relating to biomarker detection methods. One of our key innovations is the application of insulin-like growth factor binding protein-4 (IGFBP-4) fragments for predicting the risk of major adverse cardiovascular events (MACEs) in patients with acute coronary syndrome (ACS).

These fragments are generated through specific cleavage of IGFBP-4 by pregnancy-associated plasma protein-A (PAPP-A), which exerts proatherogenic activity. PAPP-A specifically cleaves IGFBP-4 between Met135 and Lys136, resulting in the formation of two proteolytic fragments:

·         NT-IGFBP-4 (N-terminal fragment)

·         CT-IGFBP-4 (C-terminal fragment)

Antibodies specific to NT-IGFBP-4 and CT-IGFBP-4 could be used for development of immunoassay methods for quantitative or qualitative detection of IGFBP-4 fragments in human blood, supporting more accurate cardiovascular risk assessment.

Hytest provides high-quality reagents for the separate detection of NT-IGFBP-4 and CT-IGFBP-4 (Cat. #4IGF4). The newest addition to this product line is recombinant IBP3m, which is specific to human NT-IGFBP-4. IBP3m can be paired with IBP144 or IBP188, as summarized in the table below.

Produced using advanced recombinant technology, IBP3m delivers reliable performance with exceptional lot-to-lot consistency. Hytest ensures a stable, long-term supply at a competitive price point, meeting the needs of your assay development.

For more detailed information, please check our Datasheet and Technotes. You could also find articles of IGFBP-4 and PAPP-A published by Hytest scientists here.